Vol. 44 | No. 2 | July-December 2016Back

Open Access

The Effect of Rabeprazole on the Antiplatelet Efficacy of Clopidogrel: A Systematic Review

Eugenio B. Reyes, April Ann Bermudez-delos Santos
Dec 2016 DOI 10.69944/pjc.d5a0e28ae9

More Info

Eugenio B. Reyes, MD1, 2; April Ann Bermudez-delos Santos, MD1 

1Section of Cardiology, Manila Doctors Hospital, Manila, Philippines 

2Section of Cardiology, Philippine General Hospital 

References
  1. Philippine Heart Association Acute Coronary Syndrome Registry.  Philipp J Cardiol 2013;1:1-23. 
  2. El-Halabi, MM, et al. CYP2C19 genetic polymorphism, rabeprazole  and esomeprazole have no effect on the antiplatelet action of  clopidogrel. J Cardiovasc Pharmacol. 2013;62:41-49. 
  3. Jia Wu, et al. Drug-drug interaction of rabeprazole and clopidogrel in  healthy Chinese volunteers. Eur J Clin Pharmacol. 2013;69:179-187.
  4. Tentzeris I, Jarai R, Farhan S, et al. Impact of concomitant treatment  with proton pump inhibitors and clopidogrel on clinical outcome  in patients after coronary stent implantation. Thromb Haemost  2010;104:1211e1218. 
  5. Hokimoto, S, et al. Impact of CYP2C19 polymorphism and proton  pump inhibitors on platelet reactivity to clopidogrel and clinical  outcomes following stent implantation. Thrombosis Research  2014;133:599-605 
  6. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008  expert consensus document on reducing the gastrointestinal risks of  antiplatelet therapy and nsaid use: a report of the American college  of cardiology foundation task force on clinical expert consensus  documents. J Am Coll Cardiol. 2008;52:1502–1517.  
  7. Shin, JM, Sachs, G. Pharmacology of proton-pump inhibitors. Curr  Gastroenterol Rep. 2008;10(6):528-534. 
  8. Drepper MD, Spahr L, Frossard JL. Clopidogrel and proton pump  inhibitors - where do we stand in 2012? World J Gastroenterol  2012;18(18): 2161-2171  
  9. Furuta, T, et al. Influences of different proton pump inhibitors on  the anti-platelet function of clopidogrel in relation to CYP2C19  genotypes. Br J Clin Pharmacol. 2010;70(3):383-392. 
  10. Siriswangvat, S, et al. Comparison between the effect of omeprazole  and rabeprazole on the antiplatelet action of clopidogrel. Circ J.  2010;74:2187-92. 
  11. Funck-Brentano C, et al. Effects of rabeprazole on the antiplatelet  effects and pharmacokinetics of clopidogrel in healthy volunteers.  Arch Cardiovasc Dis 2013; Dec;106(12):661-71. 
  12. Yamane K, et al. Effects of PPIs and an H2 blocker on the antiplatelet  function of clopidogrel in Japanese patients under dual antiplatelet  therapy. J Atheroscler Thromb, 2012;19:559-69. 
  13. Ray WA, et al. Outcomes with concurrent use of clopidogrel  and proton-pump inhibitors: a cohort study. Ann Intern Med.  2010;16:152(6):337-345 
  14. Yasu T, et al. Efficacy and safety of concomitant use of rabeprazole  during dual-antiplatelet therapy with clopidogrel and aspirin after  drug-eluting stent implantation: a retrospective cohort study.  Yakugaku Zasshi.2010;130(12):1743-50 
  15. Gaglia MA Jr, Torguson R, Hanna N, et al. Relation of proton  pump inhibitor use after percutaneous coronary intervention with  drug-eluting stents to outcomes. Am J Cardiol 2010;105:833e838. 
  16. Charlot M, et al. Proton-pump inhibitors are associated with  increased cardiovascular risk independent of clopidogrel use: a  nationwide cohort study. Ann Intern Med 2010;153 378e386. 
  17. O’Donoghue ML, et al. Pharmacodynamic effect and clinical efficacy  of clopidogrel and prasugrel with or without a proton-pump inhibitor:  an analysis of two randomised trials. Lancet 2009;374:989e997 
  18. van Boxel OS, et al. Cardiovascular and gastrointestinal outcomes in  clopidogrel users on proton pump inhibitors: results of a large Dutch  cohort study. Am J Gastroenterol 2010;105:2430e2436. 
  19. Rassen JA, et al. Cardiovascular outcomes and mortality in patients  using clopidogrel with proton pump inhibitors after percutaneous  coronary intervention or acute coronary syndrome. Circulation  2009;120:2322e2329. 
  20. Ortolani P, et al. One-year clinical outcome in patients with acute coronary syndrome treated with concomitant use of clopidogrel  and proton pump inhibitors: results from a regional cohort study.  J Cardiovasc Med (Hagerstown) 2011;. (January 19, Epub ahead  of print). 
  21. Stockl KM, et al. Risk of rehospitalization for patients using  clopidogrel with a proton pump inhibitor. Arch Intern Med  2010;170:704e710. 
  22. Sarafoff N, Sibbing D, Sonntag U, et al. Risk of drug-eluting stent  thrombosis in patients receiving proton pump inhibitors. Thromb  Haemost. 2010;104:626e632. 
  23. Kreutz RP, Stanek EJ, Aubert R, et al. Impact of proton pump  inhibitors on the effectiveness of clopidogrel after coronary stent  placement: the clopidogrel Medco outcomes study. Pharmacotherapy.  2010;30:787e796. 
  24. Wu CY, Chan FK, Wu MS, et al. Histamine2-receptor antagonists  are an alternative to proton pump inhibitor in patients receiving  clopidogrel. Gastroenterology 2010;139:1165e1171 
  25. PRISMA Flow Diagram. Moher D, Liberati A, Tetzlaff J, Altman  DG, The PRISMA Group (2009) Preferred Reporting Items for  Systematic Reviews and Meta-Analyses: The PRISMA Statement.  PLoS Med 6(6): e1000097. 
  26. Siller-Matula JM, Jilma B, Schror K, Christ G, Huber K. Effect  of proton pump inhibitors on clinical outcome in patients treated  with clopidogrel: a systematic review and meta-analysis. J Thromb  Haemost 2010;8:2624–41.  
  27. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez  G, Mansourati J, Mottier D, Abgrall JF, Boschat J. In- fluence of  omeprazole on the antiplatelet action of clopido- grel associated  with aspirin: the randomized, double-blind OCLA (Omeprazole  CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256-260  
  28. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma  B. Effects of pantoprazole and esomeprazole on platelet inhibition  by clopidogrel. Am Heart J 2009;157:e1-148.e5  
  29. Bhurke SM, Martin BC, Li C, Franks AM, Bursac Z, Said Q. Effect  of clopidogrel-proton pump inhibitor drug interaction on adverse  cardiovascular events in patients with acute coronary syndrome.  Pharmacotherapy 2012;32(9):809–818. 
  30. Ho MP, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED,  Rumsfield JS. Risk of adverse outcomes with concomitant use of  clopidogrel and proton-pump inhibitors following acute coronary  syndrome. JAMA 2009;301(9):937-944. 
  31. Lin, C, et al. Cardiovascular outcomes associated with concomitant  use of clopidogrel and proton pump inhibitors in patients with acute  coronary syndrome in Taiwan. Br J Clin Pharmacol 2012;74(5):824- 34. 
  32. Higgins JPT, et al. The Cochrane Collaboration’s tool for assessing  risk of bias in randomised trials. BMJ 2011;343:d5928 
  33. Wells GA, et al. The Newcastle-Ottawa Scale (NOS) for assessing the  quality of nonrandomised studies in meta-analyses. 2014. Available  at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
License

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits use, share — copy and redistribute the material in any medium or format, adapt — remix, transform, and build upon the material, as long as you give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.